Galecto Inc
NASDAQ:GLTO
Galecto Inc
Research & Development
Galecto Inc
Research & Development Peer Comparison
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Galecto Inc
NASDAQ:GLTO
|
Research & Development
-$23.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
Genmab A/S
CSE:GMAB
|
Research & Development
-kr8.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-31%
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Research & Development
-kr666.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-15%
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Research & Development
-€370.4m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Research & Development
-kr1.7B
|
CAGR 3-Years
-70%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
-13%
|
Bioporto A/S
CSE:BIOPOR
|
Research & Development
-kr25.1m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
See Also
What is Galecto Inc's Research & Development?
Research & Development
-23.8m
USD
Based on the financial report for Dec 31, 2023, Galecto Inc's Research & Development amounts to -23.8m USD.
What is Galecto Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-19%
Over the last year, the Research & Development growth was 51%. The average annual Research & Development growth rates for Galecto Inc have been 1% over the past three years , -19% over the past five years .